MedImmune boosted by new data on FluMist

MedImmune shares got a boost after the Maryland biotech announced the results of a new study showing some big advantages of FluMist over injected flu vaccines. Children under 5 receiving FluMist had 55 percent fewer cases of flu compared to a group getting the standard jab. FluMist is already approved for everyone who's 5 to 49.

It's all good news for MedImmune, which has struggled mightily to build a market for FluMist after initially registering a less-than-enthusiastic response from the public. MedImmune's execs right now may be spending more time mulling the news that Carl Icahn has accumulated a stake of 2.8 million shares in the biotech. Icahn recently spurred a shakeup at ImClone after gaining seats on the board.

- read the report on FluMist from the AP

Related Articles:
MedImmune touts new FluMist version. Report
FDA approves refrigerated formulation of FluMist. Report
MedImmune gets nod for new vaccine tech. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.